Regeneron Pharmaceuticals Investor Presentation — May 2021

Document content

CORPORATE PRESENTATION

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ

materially from these forward -looking statements .Words such as“anticipate,” “expect,”“intend,”“plan,”“believe,”“seek,”“estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notall

forward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business and

itsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’ ability tocontinue toconduct research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales

ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators (collectively, ”Regeneron’s Products“), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products and

product candidates being developed byRegeneron and/or itscollaborators (collectively, “Regeneron’s ProductCandidates”) andresearch andclinical programs now underway orplanned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®

(dupilumab ),Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab ),EvkeezaTM(evinacumab ),InmazebTM(atoltivimab ,maftivimab ,andodesivimab -ebgn ),REGEN -COV™(casirivimab with imdevimab ),fasinumab ,garetosmab ,pozelimab ,

odronextamab ,itepekimab ,REGN 5458 ,REGN 5713 -5714 -5715 ,Regeneron’s other oncology programs (including itscostimulatory bispecific portfolio), Regeneron’s and itscollaborators’ earlier -stage programs, and theuse ofhuman genetics in

Regeneron’s research programs ;safety issues resulting from theadministration ofRegeneron’s Products andRegeneron’s Product Candidates inpatients, including serious complications orside effects inconnection withtheuseofRegeneron’s Products

andRegeneron’s Product Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial launch ofRegeneron’s Product Candidates andnew indications forRegeneron’s Products, including without limitation

those listed above ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs conducted byRegeneron and/or itscollaborators may be

replicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory approval ;ongoing regulatory obligations andoversight impacting Regeneron’s Products (such asEYLEA, Dupixent,